......		Meeting Location: Emerging Enterprise Center at Foley Hoag the Bay Colony Corporate Center 1000 Winter Street, Suite 4000 (North Entrance) Waltham, MA  Meeting Time: 6:30 - 9:30 pm Meeting Cost: $25 public, $10 students and active military Map and Directions
	Tuesday, September 16, 2008 Selling Vision and Innovation in the Life Sciences Sector - "Senior executives and investors speak out on how to get your first early stage sale" Register Online Meeting Overview The September 16th EntreTech forum kicks off the Forum's monthly panel series for 2008-2009 with a focus on the real-world challenge of managing early-stage sales in the bio-pharma sector. As academic researchers attempt to commercialize their work, perhaps the most relevant acid test is the first sale. The September 16th EntreTech Forum panel members will explore the issue of early product sales, bringing together the leadership and backers of early stage biopharma innovators. Join us for a terrific kick-off to the EntreTech Forum's 2008-2009 calendar year. Panelist:  Omar Amirana, M.D., Investment Manager – Oxford Biosciences, http://www.oxbio.com/ Dr. Amirana is an Investment Manager for Oxford. Prior to joining Oxford in 2005, he served as the Vice President of Business Development at St. Jude Medical (STJ) in the Cardiology and Daig Divisions where he was responsible for mergers, acquisitions and licenses in the areas of electrophysiology, interventional cardiology and peripheral vascular intervention. Prior to joining St. Jude Medical, Dr. Amirana was the CEO of Resolution Medical, a privately held cardiology company in Silicon Valley. He has helped raise over $60M in venture financing and was part of the management team in four start-up healthcare technology companies. Three of those companies have held IPOs: EP Technologies, Cardima, and MedicaLogic/Medscape. Dr. Amirana was a co-founder of Cardima, a spin-off of Target Therapeutics which achieved a market capitalization of $150M. He served there for seven years as Vice President of Marketing and Business Development and as Chief Technical Officer. He was Vice President of Marketing at MedicaLogic which raised $101M in its IPO, achieved ~$1.1B market capitalization and acquired Medscape and Total eHealth. Dr. Amirana has launched cardiovascular products worldwide and holds various patents. He received a B.S. in Mechanical Engineering from Tufts University and an M.D. from Eastern Virginia Medical School. He led the firm’s investment in Nfocus Neuromedical (neurovascular implant technology) and serves on its board. He is also a board member of Flowmedica (targeted renal therapy) and CardioFocus (atrial fibrillation catheter therapy). Errik Anderson, VP Operations & Finance – Adimab, http://www.adimab.com/ Mr. Anderson is a founding member of Adimab, a privately held company, and current serves as Vice President of Operations & Finance. Adimab is changing the discovery, maturation and production of fully human therapeutic antibodies. By integrating all aspects of antibody discovery and developing sophisticated screening methods, Adimab rapidly selects high affinity human antibodies with improved formulation and manufacturing characteristics. Their proprietary library design and presentation technologies enable the discovery of full-length human antibodies with broad epitope coverage and high affinity - faster than any known technology platform. Adimab was founded by two of the world's leading yeast biotechnologists: Professor Tillman Gerngross (Dartmouth, Co-founder of GlycoFi, Inc., a wholly owned subsidiary of Merck & Co. since 2006) who led the humanization effort to engineer yeast for the production of human glycoproteins, and Professor Dane Wittrup (MIT, Co-founder of Biodisplay, acquired by Abbott Labs in 2001) who pioneered yeast surface display for the discovery and maturation of antibody fragments. Prior to Adimab, Mr. Anderson was at Lehman Brothers Venture Capital in New York City and in 2003 was the founding President of a small venture capital consulting and investment partnership, Seven West Ventures. Errik pursued graduate studies in bioengineering at the Thayer School of Engineering, received his MBA from the Tuck School of Business at Dartmouth College and his A.B. in Economics from Dartmouth College. Glenn Batchelder, President and Chief Executive Officer – BIND Biosciences, http://www.bindbio.com/ Mr. Batchelder leads BIND Biosciences as president and CEO of this biopharmaceutical company developing therapeutic targeted nanoparticles.  BIND leverages the convergence of polymeric biomaterials, nanoparticle engineering, and combinatorial synthesis to enable optimally targeted nanoparticles for specific indications, concentrating the drug at the site of disease while minimizing systemic exposure. Initial product development efforts are in cardiovascular disease and cancer. Prior to joining BIND Biosciences, Mr. Batchelder was CEO of Acceleron Pharma, a company developing biotherapeutics for cancer and musculoskeletal disorders. He grew Acceleron from a research start-up to a clinical stage company with promising bone loss therapy in the clinic and a robust preclinical pipeline. Prior to Acceleron, Mr. Batchelder was Senior Vice President of Operations at Millennium Pharmaceuticals where he played an integral leadership role in the launch of VELCADE and was responsible for the commercial supply chain and technical operations for INTEGRILIN. Mr. Batchelder is on the Board of Directors of the Massachusetts Biotechnology Council. He received a B.S. in Chemical Engineering from Lehigh University. Thomas M. Fitzgerald, CEO CellTraffix, http://celltraffix.com/ As CEO of CellTraffix, Mr. Fitzgerald leverages his 25+ years of sector experience to direct the strategic activities of this privately held development-stage medical technology company.  CellTraffix is focused on bringing novel kits and therapeutic products to market to serve the oncology and adult stem cell markets. Prior to CellTraffix, Mr. Fitzgerald has served as President and CEO of Oyagen, a biotechnology company focused on discovering, developing, and commercializing novel pharmaceutical therapies exploiting RNA editing and DNA editing enzymes.  Mr. Fitzgerald was also COO of Sheffield Medical, where he was responsible for developing and executing business strategies designed to expedite commercialization of the Company's product portfolio and expanding the range of corporate activities.  Previously, Mr. Fitzgerald also served seven years at Fisons Corp. as VP & General Counsel. During that time, Fisons Corp., located in Rochester, NY, was the largest, most profitable operating unit of the UK-based ethical pharmaceutical company, Fisons Group plc. Mr. Fitzgerald oversaw legal, regulatory and governmental relations of the American unit, as well as U.S. activities of Fisons Group. He was instrumental in enhancing this company's relations with the FDA, establishing the U.S. unit's first internal legal department, and developing commercial objectives and strategy for key corporate acquisitions and business sales. In addition to these positions, he served on the Board of Directors of Fisons Corp., Fisons Holdings, Inc. and Pharmasol Corp. Mr. Fitzgerald has also previously served as internal counsel at SmithKline Beecham plc (SKB; formerly, Beecham, Inc.), eventually attaining the position of Assistant General Counsel. In this role, he provided legal counsel for SKB's ethical pharmaceutical business and consumer products business in the western hemisphere. Mr. Fitzgerald has also been internal legal counsel at Mobil Corp. and Hertz Corp.  Keith Batchelder, Founder and CEO, Genomic Healthcare Strategies Keith Batchelder is the founder and CEO of Genomic Healthcare Strategies, a company focused on the changes in healthcare resulting from advances in molecular medicine.  Dr. Batchelder has served as chief technical officer of WorldCare International Clinical Trials, as CIO of Harvard Salud Integral, as a principal of AMICAS Corp, and at Massachusetts General Hospital for eight years.  Dr. Batchelder was educated at Middlebury College, the Hahnemann University School of Medicine, received postgraduate training in Medical Informatics at The Boston VA Hospital and completed a fellowship at the Food and Drug Administration.  He also holds a masters degree in biomaterials from New York University. Register Online
Lawrence C. Grumer | Tel: 617-325-9852 | e-Fax: 484-303-9852 | lgrumer@taacorp.com